| Year |
Citation |
Score |
| 2024 |
Low JT, Brown MC, Reitman ZJ, Bernstock JD, Markert JM, Friedman GK, Waitkus MS, Bowie ML, Ashley DM. Understanding and therapeutically exploiting cGAS/STING signaling in glioblastoma. The Journal of Clinical Investigation. 134. PMID 38226619 DOI: 10.1172/JCI163452 |
0.396 |
|
| 2023 |
Koschmann C, Al-Holou WN, Alonso MM, Anastas J, Bandopadhayay P, Barron T, Becher O, Cartaxo R, Castro MG, Chung C, Clausen M, Dang D, Doherty R, Duchatel R, Dun M, ... ... Reitman ZJ, et al. A road map for the treatment of pediatric diffuse midline glioma. Cancer Cell. PMID 38039965 DOI: 10.1016/j.ccell.2023.11.002 |
0.547 |
|
| 2023 |
Tu KJ, Diplas BH, Regal JA, Waitkus MS, Pirozzi CJ, Reitman ZJ. Mining cancer genomes for change-of-metabolic-function mutations. Communications Biology. 6: 1143. PMID 37950065 DOI: 10.1038/s42003-023-05475-w |
0.426 |
|
| 2023 |
Mangoli A, Wu S, Liu HQ, Aksu M, Jain V, Foreman BE, Regal JA, Weidenhammer LB, Stewart CE, Guerra Garcia ME, Hocke E, Abramson K, Williams NT, Luo L, Deland K, ... ... Reitman ZJ, et al. ( ) disruption sensitizes spatially-directed H3.3K27M/TP53 diffuse midline gliomas to radiation therapy. Biorxiv : the Preprint Server For Biology. PMID 37904990 DOI: 10.1101/2023.10.18.562892 |
0.455 |
|
| 2023 |
Jones JK, Zhang H, Lyne AM, Cavalli FMG, Hassen WE, Stevenson K, Kornahrens R, Yang Y, Li S, Dell S, Reitman ZJ, Herndon JE, Hoj J, Pendergast AM, Thompson EM. ABL1 and ABL2 promote medulloblastoma leptomeningeal dissemination. Neuro-Oncology Advances. 5: vdad095. PMID 37781087 DOI: 10.1093/noajnl/vdad095 |
0.35 |
|
| 2023 |
Tu KJ, Stewart CE, Hendrickson PG, Regal JA, Kim SY, Ashley DM, Waitkus MS, Reitman ZJ. Pooled genetic screens to identify vulnerabilities in TERT-promoter-mutant glioblastoma. Oncogene. PMID 37741952 DOI: 10.1038/s41388-023-02845-w |
0.309 |
|
| 2023 |
Regal JA, Guerra García ME, Jain V, Chandramohan V, Ashley DM, Gregory SG, Thompson EM, López GY, Reitman ZJ. Ganglioglioma deep transcriptomics reveals primitive neuroectoderm neural precursor-like population. Acta Neuropathologica Communications. 11: 50. PMID 36966348 DOI: 10.1186/s40478-023-01548-3 |
0.403 |
|
| 2022 |
Stewart CE, Guerra-García ME, Luo L, Williams NT, Ma Y, Regal JA, Ghosh D, Sansone P, Oldham M, Deland K, Becher OJ, Kirsch DG, Reitman ZJ. The Effect of Loss on Radiosensitivity of a Primary Mouse Model of -Deleted Brainstem Glioma. Cancers. 14. PMID 36139666 DOI: 10.3390/cancers14184506 |
0.507 |
|
| 2022 |
Khadka P, Reitman ZJ, Lu S, Buchan G, Gionet G, Dubois F, Carvalho DM, Shih J, Zhang S, Greenwald NF, Zack T, Shapira O, Pelton K, Hartley R, Bear H, et al. PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation. Nature Communications. 13: 604. PMID 35105861 DOI: 10.1038/s41467-022-28198-8 |
0.443 |
|
| 2021 |
Deland K, Mercer JS, Crabtree DM, Garcia MEG, Reinsvold M, Campos LDS, Williams NT, Luo L, Ma Y, Reitman ZJ, Becher OJ, Kirsch DG. Radiosensitizing the Vasculature of Primary Brainstem Gliomas Fails to Improve Tumor Response to Radiotherapy. International Journal of Radiation Oncology, Biology, Physics. PMID 34619331 DOI: 10.1016/j.ijrobp.2021.09.047 |
0.318 |
|
| 2021 |
Yu S, Wei S, Savani M, Lin X, Du K, Mender I, Siteni S, Vasilopoulos T, Reitman ZJ, Ku Y, Wu D, Liu H, Tian M, Chen Y, Labrie M, et al. A Modified Nucleoside 6-thio-2'-deoxyguanosine Exhibits Anti-tumor Activity in Gliomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34593527 DOI: 10.1158/1078-0432.CCR-21-0374 |
0.379 |
|
| 2019 |
Reitman ZJ, Paolella BR, Bergthold G, Pelton K, Becker S, Jones R, Sinai CE, Malkin H, Huang Y, Grimmet L, Herbert ZT, Sun Y, Weatherbee JL, Alberta JA, Daley JF, et al. Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells. Nature Communications. 10: 3731. PMID 31427603 DOI: 10.1038/S41467-019-11493-2 |
0.442 |
|
| 2018 |
Reitman ZJ, Winkler F, Elia AEH. New Directions in the Treatment of Glioblastoma. Seminars in Neurology. 38: 50-61. PMID 29548052 DOI: 10.1055/s-0038-1623534 |
0.3 |
|
| 2018 |
Chitneni SK, Reitman ZJ, Spicehandler R, Gooden DM, Yan H, Zalutsky MR. Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors. Bioorganic & Medicinal Chemistry Letters. PMID 29366652 DOI: 10.1016/J.Bmcl.2018.01.015 |
0.387 |
|
| 2016 |
Song ZJ, Reitman ZJ, Ma ZY, Chen JH, Zhang QL, Shou XF, Huang CX, Wang YF, Li SQ, Mao Y, Zhou LF, Lian BF, Yan H, Shi YY, Zhao Y. The genome-wide mutational landscape of pituitary adenomas. Cell Research. PMID 27670697 DOI: 10.1038/cr.2016.114 |
0.363 |
|
| 2016 |
Chitneni SK, Reitman ZJ, Gooden DM, Yan H, Zalutsky MR. Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs. European Journal of Medicinal Chemistry. 119: 218-230. PMID 27163884 DOI: 10.1016/J.Ejmech.2016.04.066 |
0.352 |
|
| 2015 |
Reitman ZJ, Sinenko SA, Spana EP, Yan H. Genetic dissection of leukemia-associated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in Drosophila. Blood. 125: 336-45. PMID 25398939 DOI: 10.1182/blood-2014-05-577940 |
0.308 |
|
| 2014 |
Reitman ZJ, Duncan CG, Poteet E, Winters A, Yan LJ, Gooden DM, Spasojevic I, Boros LG, Yang SH, Yan H. Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia. The Journal of Biological Chemistry. 289: 23318-28. PMID 24986863 DOI: 10.1074/Jbc.M114.575183 |
0.393 |
|
| 2014 |
Zhang L, Chen LH, Wan H, Yang R, Wang Z, Feng J, Yang S, Jones S, Wang S, Zhou W, Zhu H, Killela PJ, Zhang J, Wu Z, Li G, ... ... Reitman ZJ, et al. Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas. Nature Genetics. 46: 726-30. PMID 24880341 DOI: 10.1038/Ng.2995 |
0.523 |
|
| 2014 |
Killela PJ, Pirozzi CJ, Healy P, Reitman ZJ, Lipp E, Rasheed BA, Yang R, Diplas BH, Wang Z, Greer PK, Zhu H, Wang CY, Carpenter AB, Friedman H, Friedman AH, et al. Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget. 5: 1515-25. PMID 24722048 DOI: 10.18632/Oncotarget.1765 |
0.438 |
|
| 2014 |
Killela PJ, Pirozzi CJ, Reitman ZJ, Jones S, Rasheed BA, Lipp E, Friedman H, Friedman AH, He Y, McLendon RE, Bigner DD, Yan H. The genetic landscape of anaplastic astrocytoma. Oncotarget. 5: 1452-7. PMID 24140581 DOI: 10.18632/Oncotarget.1505 |
0.375 |
|
| 2013 |
Reitman ZJ, Pirozzi CJ, Yan H. Promoting a new brain tumor mutation: TERT promoter mutations in CNS tumors. Acta Neuropathologica. 126: 789-92. PMID 24217890 DOI: 10.1007/s00401-013-1207-5 |
0.45 |
|
| 2013 |
Pirozzi CJ, Reitman ZJ, Yan H. Releasing the block: setting differentiation free with mutant IDH inhibitors. Cancer Cell. 23: 570-2. PMID 23680144 DOI: 10.1016/j.ccr.2013.04.024 |
0.323 |
|
| 2013 |
Bettegowda C, Agrawal N, Jiao Y, Wang Y, Wood LD, Rodriguez FJ, Hruban RH, Gallia GL, Binder ZA, Riggins CJ, Salmasi V, Riggins GJ, Reitman ZJ, Rasheed A, Keir S, et al. Exomic sequencing of four rare central nervous system tumor types. Oncotarget. 4: 572-83. PMID 23592488 DOI: 10.18632/Oncotarget.964 |
0.433 |
|
| 2013 |
Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proceedings of the National Academy of Sciences of the United States of America. 110: 6021-6. PMID 23530248 DOI: 10.1093/Neuonc/Nou206.18 |
0.493 |
|
| 2013 |
Jin G, Reitman ZJ, Duncan CG, Spasojevic I, Gooden DM, Rasheed BA, Yang R, Lopez GY, He Y, McLendon RE, Bigner DD, Yan H. Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. Cancer Research. 73: 496-501. PMID 23204232 DOI: 10.1158/0008-5472.Can-12-2852 |
0.389 |
|
| 2012 |
Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, Rodriguez FJ, Rosemberg S, Oba-Shinjo SM, Nagahashi Marie SK, Bettegowda C, Agrawal N, Lipp E, Pirozzi C, Lopez G, et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget. 3: 709-22. PMID 22869205 DOI: 10.18632/Oncotarget.588 |
0.459 |
|
| 2011 |
Jin G, Reitman ZJ, Spasojevic I, Batinic-Haberle I, Yang J, Schmidt-Kittler O, Bigner DD, Yan H. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations. Plos One. 6: e16812. PMID 21326614 DOI: 10.1371/Journal.Pone.0016812 |
0.372 |
|
| 2011 |
Reitman ZJ, Jin G, Karoly ED, Spasojevic I, Yang J, Kinzler KW, He Y, Bigner DD, Vogelstein B, Yan H. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proceedings of the National Academy of Sciences of the United States of America. 108: 3270-5. PMID 21289278 DOI: 10.1073/Pnas.1019393108 |
0.478 |
|
| 2010 |
Lopez GY, Reitman ZJ, Solomon D, Waldman T, Bigner DD, McLendon RE, Rosenberg SA, Samuels Y, Yan H. IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. Biochemical and Biophysical Research Communications. 398: 585-7. PMID 20603105 DOI: 10.1016/J.Bbrc.2010.06.125 |
0.445 |
|
| 2010 |
Reitman ZJ, Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. Journal of the National Cancer Institute. 102: 932-41. PMID 20513808 DOI: 10.1093/jnci/djq187 |
0.38 |
|
| 2010 |
Reitman ZJ, Parsons DW, Yan H. IDH1 and IDH2: not your typical oncogenes. Cancer Cell. 17: 215-6. PMID 20227034 DOI: 10.1016/j.ccr.2010.02.024 |
0.315 |
|
| 2010 |
Reitman ZJ, Olby NJ, Mariani CL, Thomas R, Breen M, Bigner DD, McLendon RE, Yan H. IDH1 and IDH2 hotspot mutations are not found in canine glioma. International Journal of Cancer. Journal International Du Cancer. 127: 245-6. PMID 19877121 DOI: 10.1002/Ijc.25017 |
0.42 |
|
| Show low-probability matches. |